The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification

PURPOSE: Capmatinib, an oral MET kinase inhibitor, has demonstrated its efficacy against non–small cell lung cancer (NSCLC) with MET dysregulation. We investigated its clinical impact in advanced NSCLC with MET exon 14 skipping mutation (METex14) or gene amplification. MATERIALS AND METHODS: Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Wonyoung, Park, Seog-Yun, Lee, Youngjoo, Lim, Kun Young, Park, Minjoung, Lee, Geon Kook, Han, Ji-Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524022/
https://www.ncbi.nlm.nih.gov/pubmed/33540494
http://dx.doi.org/10.4143/crt.2020.1331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524022/
https://www.ncbi.nlm.nih.gov/pubmed/33540494
http://dx.doi.org/10.4143/crt.2020.1331

Ejemplares similares